Abstract
This review provides an overview of the currently used nuclear medicine imaging modalities and ongoing developments in the imaging of neuroendocrine tumors (NETs). Most NETs overexpress the somatostatin receptor mainly sst2. Somatostatin receptor scintigraphy with 111In-DTPA-0octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic NETs. The use of 68Ga-labeled analogs of octreotide for PET imaging, with of different radiolabelled somatostatin analogues with higher affinity and different affinity profiles to the somatostatin receptor subtypes such as DOTATOC, DOTANOC, and DOTA-TATE, are in clinical application in nuclear medicine. The development PET tracers for NET imaging include Fluorodihydroxyphenylalanine (18FDOPA) and fluorodeoxyglucose (18FDG). 18FDOPA-PET appears to be a major tool for the management of carcinoid tumors with excellent diagnostic performances. The role of 18FFDG PET-CT in the prognosis of neuroendocrine tumors should be evaluated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localisation of endocrine-related tumours with radioiodinated analog of somatostatin. Lancet 1(8632):242–244
Lamberts SW, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323(18):1246–1249
Reubi JC, Kvols L, Krenning E, Lamberts SW (1991) In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol 30(4):463–468
Patel YC, Srikant CB (1994) Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1–5). Endocrinology 135(6):2814–2817
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 20(8):716–731
Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40(2):78–88
Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP (2010) Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17(1):R53–R73
Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA (2003) Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med 44(8):1315–1321
Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L (2008) Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26(6):963–970
Pepe G, Moncayo R, Bombardieri E, Chiti A (2012) Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging. 39(Suppl 1):S41–S51. doi:10.1007/s00259-011-2019-2 (Review. PubMed PMID: 22388628)
Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, Vullierme MP, Couvelard A, Belghiti J, Ruszniewski P, Le Guludec D (2009) Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer 16(3):977–990
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):2124–2130
Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, Boucher E, Raoul JL (2009) Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50(6):858–864
Ambrosini V, Campana D, Tomassetti P, Fanti S (2012) 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 39(Suppl 1):S52–S60
Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, Rougier P, Duron F, Bouchard P, Grangé JD, Houry S, Talbot JN (2009) Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 94(4):1295–1301
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A (2010) 18F-Fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 16(3):978–985
Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E (2011) Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10 %) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 96(3):665–671
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag France
About this chapter
Cite this chapter
Lebtahi, R. (2014). Scintigraphy in Endocrine Tumors of the Gut. In: Raymond, E., Faivre, S., Ruszniewski, P. (eds) Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract. Springer, Paris. https://doi.org/10.1007/978-2-8178-0430-9_1
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0430-9_1
Published:
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0429-3
Online ISBN: 978-2-8178-0430-9
eBook Packages: MedicineMedicine (R0)